FDA
-
-
-
-
-
-
-
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
-
-
-
-
-
-
-
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
-
-
-
-
-
-
-
Allogene Therapeutics Appoints Earl Douglas as General Counsel
-
-
-
-
-
-
-
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
-
-
-
-
-
-
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
-
-
-
-
-
-
-
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
-
-
-
-
-
-
-
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
-
251,631 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All